Tucanat Tucatinib 150mg Tablets

Description

Tucanat 150mg Tablet

INTRODUCTION OF Tucanat 150mg Tablet:

Tucanat 150 mg Tablet contains Tucatinib, a targeted anticancer medicine belonging to the class of tyrosine kinase inhibitors (TKIs). It is specifically designed to block the activity of the HER2 (human epidermal growth factor receptor 2) protein, which is often overexpressed in certain cancers, especially breast cancer.

This medicine is generally prescribed in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, including those whose cancer has spread to the brain. Tucanat is typically used when the disease has progressed after at least two prior anti-HER2 treatment regimens.

By selectively inhibiting HER2-driven signaling pathways, Tucanat helps to slow down or stop the growth of cancer cells, improve survival outcomes, and manage symptoms. Being an oral therapy, it offers convenience compared to traditional intravenous chemotherapy and has shown proven benefits in clinical trials, such as prolonging life expectancy and delaying disease progression.

USES OF Tucanat 150mg Tablet

· Advanced or Metastatic Breast Cancer

· Breast Cancer with Brain Metastases

BENEFITS OF TUCANAT 150MG TABLET   

Proven survival benefit: Demonstrated improvements in overall survival and progression-free survival, even in heavily pre-treated patients, as evidenced in the HER2CLIMB clinical trial

Effectiveness against brain metastases: One of the few HER2-targeted therapies shown to penetrate the blood–brain barrier and control both treated and untreated brain lesions

Efficacy after resistance to prior HER2 therapies: Remains effective when other HER2-targeted treatments (like trastuzumab or pertuzumab) have stopped working

Convenient oral formulation: Can be taken at home, reducing the need for frequent hospital visits

MECHANISM OF ACTION TUCANAT 150MG TABLET

Tucanat 150mg Tablet belongs to a group of medicines known as tyrosine kinase inhibitors (TKIs). It works by:

Specifically targeting the HER2 receptor, a protein that promotes cancer cell growth

Blocking HER2-related signaling pathways that drive tumor progression

Working synergistically with other anticancer drugs like trastuzumab and capecitabine

Crossing the blood-brain barrier to treat cancer that has spread to the brain

This focused mechanism helps slow disease progression while minimizing impact on normal cells.